Author: Leigh MacMillan

From left, J.Court Reese, Stephanie Moore-Lotridge, PhD, Breanne Gibson, PhD, and Jonathan Schoenecker, MD, PhD, are discovering ways to prevent adverse outcomes in orthopaedic surgery.

Study identifies molecular trigger of severe injury-induced inflammatory response

Jan. 19, 2022—Vanderbilt researchers have discovered that early inappropriate activation of the enzyme plasmin caused by severe injury is a trigger of systemic inflammatory response syndrome and resulting organ failure.

H. pylori, lipid loss and stomach cancer

Jan. 17, 2022—H. pylori infection — a strong risk factor for stomach cancer — changes the composition of stomach lipids, which could offer new biomarkers for detecting premalignant changes, Vanderbilt researchers discovered.

Salmonella overcomes host resistance

Jan. 13, 2022—The invading pathogen Salmonella, a common cause of food poisoning, can change its metabolism to overcome host resistance to its colonization.

Study finds similar success rates with two devices for breathing tube placement

Dec. 15, 2021—Two devices for placing a breathing tube during critical illness had similar success rates for intubation on the first attempt, according to a study published Dec. 8 in JAMA.

Immune landscape in adrenal cancer

Dec. 14, 2021—The profile of immune-related gene expression and tumor-infiltrating immune cells in adrenocortical cancer suggests targets for new treatment strategies.

Oral microbes and gastric cancer

Dec. 13, 2021—Studies in three large population cohorts that include Asian, African American and European American people support a role for the oral microbiota — the collection of microbial species in the mouth — in gastric cancer development.

Cell signaling targets in leukemia

Dec. 9, 2021—Vanderbilt researchers identified a critical role for IL-1beta signaling in leukemia cells with a certain mutation, suggesting this pathway may be a good target for novel treatments.

Prostate cancer treatment regret

Dec. 9, 2021—Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

International study supports dupilumab for treatment of moderate-to-severe asthma in children

Dec. 8, 2021—In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.